Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD - PR Newswire UK

Submitted by Anonymous (not verified) on Tue, 04/12/2022 - 11:55

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD PR Newswire UK

Log in to post comments